Pfizer tops earnings estimates, hikes full-year guidance as Covid products help sales
Novartis' $2.9B MorphoSys bet stumbles as safety signal delays filing by years
GSK to pay $300M to license drug it sees as potential lupus treatment
How AZ’s respiratory wins are ramping up for a bigger prize in COPD
*please scroll down for all the latest news*
